Skip to Main Content

Paper Details

Effect of Alirocumab on Incidence of Atrial Fibrillation After Acute Coronary Syndromes: Insights from the ODYSSEY OUTCOMES Trial.
Am J Med
0
2022
Author NameAffiliation
Renato D LopesDuke University Medical Center, Duke Clinical Research Institute
Deepak L BhattBrigham and Women's Hospital Heart & Vascular Center and Harvard Medical School
Robert A HarringtonStanford Center for Clinical Research, Stanford University
  • 1 - 3

Datasets